Jennerex, Inc.
Records under this name other than patents Jennerex, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 9 of 9 · Back to Jennerex, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,180,149 | Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,180,151 | Oncolytic vaccinia virus combination cancer therapy Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,719,105 | Methods and compositions for production of vaccinia virus Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,980,246 | Oncolytic Vaccinia Virus Cancer Therapy Term ended Term ended Sep 7, 2026 · Medium confidence | Term ended | Term ended Sep 7, 2026 | Medium confidence |
| US 9,226,977 | Oncolytic vaccinia virus cancer therapy Formerly held Term ended Ended no later than Sep 7, 2026 · USPTO record | Term ended | Ended no later than Sep 7, 2026 | USPTO record |
| US 8,747,837 | Oncolytic vaccinia virus combination cancer therapy Formerly held Lapsed on the fee record Ended Jun 10, 2026 · USPTO record | Lapsed on the fee record | Ended Jun 10, 2026 | USPTO record |
| US 9,919,047 | Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus Formerly held Lapsed on the fee record Ended Mar 20, 2026 · USPTO record | Lapsed on the fee record | Ended Mar 20, 2026 | USPTO record |
| US 8,986,674 | Methods and Compositions Concerning Poxviruses and Cancer Formerly held Term ended Term ended Dec 16, 2023 · Medium confidence | Term ended | Term ended Dec 16, 2023 | Medium confidence |
| US 8,329,164 | Methods and compositions concerning poxviruses and cancer Formerly held Term ended Term ended Aug 11, 2023 · USPTO record | Term ended | Term ended Aug 11, 2023 | USPTO record |